DGAP-Adhoc: Dermapharm Holding SE: binding offer to acquire Arkopharma Group

2022. július 30., szombat, 20:22





DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Takeover


Dermapharm Holding SE: binding offer to acquire Arkopharma Group


30-Jul-2022 / 20:22 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)

No. 596/2014 on market abuse, as amended

(Market Abuse Regulation – MAR)




Dermapharm Holding SE: binding offer to acquire Arkopharma Group



Grünwald, July 30, 2022 – Today, Dermapharm AG, wholly owned subsidiary of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8), offered to acquire 100% of the shares in Apharma TopCo SAS, headquartered in Carros, France, from private equity firm Montagu and minority shareholders of the target, for a purchase price approximating EUR 450 million.



Apharma TopCo SAS is the holding company of the Arkopharma Group, a provider of herbal OTC products and dietary supplements in France and other European countries. In the financial year 2021, Arkopharma Group achieved sales of approximately EUR 191 million. For the current financial year 2022, it forecasts sales of slightly over EUR 200 million.



The execution of the corresponding share purchase agreement is subject to the consultation of the works council of certain French companies of the Arkopharma Group. The Management Board expects the transaction to be completed at the beginning of January 2023.



>End of the Ad hoc announcement <



 



Contact



Investor Relations & Corporate Communications

Britta Hamberger

Phone: +49 (0)89 – 64186-233

E-Mail: ir@dermapharm.com



 











30-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



























Language: English
Company: Dermapharm Holding SE

Lil-Dagover-Ring 7

82031 Grünwald

Germany
Phone: +49 (0)89 64 86-0
E-mail: ir@dermapharm.com
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1409691





 
End of Announcement DGAP News Service




1409691  30-Jul-2022 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=1409691&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.